A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Blood Pressure Reduction, With Ambulatory Blood Pressure Monitoring (ABPM), Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Hypertension and Type 2 Diabetes Mellitus

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Blood Pressure Reduction, With Ambulatory Blood Pressure Monitoring (ABPM), Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Hypertension and Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Hypertension; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 10 Dec 2015 Primary endpoint (Change in mean 24-hour systolic blood pressure (SBP) by Ambulatory Blood Pressure Monitoring (ABPM) has been met as per results published in the Journal of Clinical Hypertension (Greenwich).
    • 10 Dec 2015 Results published in the Journal of Clinical Hypertension (Greenwich)
    • 13 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top